Compare JELD & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JELD | TLSA |
|---|---|---|
| Founded | 1960 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Forest Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.7M | 145.1M |
| IPO Year | 2016 | 2017 |
| Metric | JELD | TLSA |
|---|---|---|
| Price | $0.84 | $0.56 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $1.23 | ★ $7.88 |
| AVG Volume (30 Days) | ★ 1.2M | 488.0K |
| Earning Date | 11-03-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,211,181,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.14 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.93 | $0.57 |
| 52 Week High | $3.27 | $1.90 |
| Indicator | JELD | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 28.94 | 27.95 |
| Support Level | N/A | N/A |
| Resistance Level | $1.48 | $1.21 |
| Average True Range (ATR) | 0.15 | 0.08 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 1.56 | 2.13 |
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.